Acumen Pharmaceuticals (ABOS) AI Stock Analysis

• Market Cap: $148.40M
• Dividend Yield: N/A
• Average Volume (3M): 415.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.30
• Revenue Growth: N/A
• EPS Growth: -60.99%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 60,573,425
• 10 Day Avg. Volume: 506,634
• 30 Day Avg. Volume: 415,590
• PEG Ratio: -0.02
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.73K
• Enterprise Value/Ebitda: -0.93
• 1Y Price Target: $7.00
• Price Target Upside: 211.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $3.00 ▲(33.33% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and worsening cash burn that elevates dilution risk). This is partially offset by a constructive earnings-call outlook (clear clinical milestones and cash runway into early 2027) and supportive technical trend, though momentum appears overbought. Valuation signals are limited due to negative earnings and no dividend yield.

Positive Factors

Clinical Progress: ALTITUDE-AD Phase II

The fully enrolled Phase II ALTITUDE-AD trial with topline results targeted for late 2026 is a durable de-risking milestone. A positive outcome could validate the Aβ oligomer approach, enable partnerships or regulatory discussions, and materially shift Acumen from R&D toward commercialization.

Strategic collaboration and EBD platform

The JCR collaboration and addition of an EBD-linked candidate (ACU234) build a differentiated delivery platform. Improved brain exposure technology can increase success odds across antibody assets, strengthen competitive positioning, and expand licensing or co-development avenues over the medium term.

Near-term cash runway and cost discipline

Holding $136.1M in cash and securities and reporting reduced CRO and G&A expenses gives Acumen a multi-quarter runway to reach key inflection points (preclinical EBD data, Phase II topline). This preserves operational focus and reduces immediate financing urgency while executing critical programs.

Negative Factors

Pre-revenue profile and widening losses

Acumen remains pre-revenue with materially widening losses (-$133.4M TTM), leaving future sustainability dependent on trial success or partnerships. This structural revenue absence magnifies execution and financing risk and reduces visibility into any path to persistent profitability over the coming quarters.

Accelerating cash burn

Operating cash outflows have accelerated to -$123.7M TTM, with free cash flow tracking losses. Persistent negative cash generation constrains strategic options, increases reliance on external capital, and raises the probability of dilutive financings unless spending meaningfully slows or new funding sources are secured.

Weakened equity base and financing risk

Shareholders' equity has declined substantially (≈$267M to $93.2M), reflecting cumulative losses and prior financings. A thinner equity cushion limits debt capacity, increases dependence on equity raises, and amplifies dilution and governance pressures, making long-term program continuity contingent on successful milestones or partnerships.

Acumen Pharmaceuticals Business Overview & Revenue Model

Company Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

How the Company Makes Money

Acumen Pharmaceuticals generates revenue primarily through funding from investors, partnerships, and collaborations rather than traditional product sales, as it is still in the clinical trial phase. The company relies on strategic alliances with pharmaceutical companies, research institutions, and government grants to support its research and development activities. Additionally, Acumen may receive milestone payments and royalties from potential future licensing agreements for its drug candidates, contingent upon successful clinical development and regulatory approval.

Acumen Pharmaceuticals Financial Statement Overview

Summary

Pre-revenue profile with $0 revenue and materially widening losses (net income down to -$133.4M TTM) alongside accelerating cash burn (operating cash flow -$123.7M TTM). Balance sheet leverage is modest versus equity, but equity has declined sharply over time, raising financing/dilution risk.

Income Statement

ABOS remains a pre-revenue biotech, with $0 revenue in both annual periods (2021–2024) and TTM (Trailing-Twelve-Months). Losses have widened meaningfully versus 2022–2023, with net income falling from -$52.4M (2023) to -$102.3M (2024) and -$133.4M in TTM (Trailing-Twelve-Months), pointing to a rising expense base. The primary strength is that losses are consistent with an R&D-stage profile, but the clear weakness is the lack of commercialization revenue and increasing operating losses, which reduces visibility on the path to profitability.

Balance Sheet

Leverage appears manageable in absolute terms, with total debt at ~$30.8M in TTM (Trailing-Twelve-Months) against ~$93.2M of equity, and debt-to-equity improving versus 2024 (lower in TTM). However, the balance sheet has weakened over time as equity declined from ~$267.0M (2023) to ~$181.8M (2024) to ~$93.2M in TTM (Trailing-Twelve-Months), consistent with ongoing losses and cash burn. Overall, the company is not highly levered, but shrinking equity and negative returns increase dilution/financing risk.

Cash Flow

Cash burn is significant and accelerating, with operating cash flow of -$43.1M (2023), -$86.2M (2024), and -$123.7M in TTM (Trailing-Twelve-Months); free cash flow tracks closely at -$123.7M in TTM (Trailing-Twelve-Months). A relative positive is that cash flow is broadly in line with reported losses (free cash flow roughly matches net income), suggesting limited non-cash distortion. The key weakness is the scale and worsening trajectory of cash outflows, which likely necessitates additional capital raises unless spending slows materially.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	1.44M
Gross Profit	-44.00K	0.00	0.00	-169.00K	-12.30M	-6.56M
EBITDA	-129.04M	-98.08M	-51.61M	-42.69M	-19.58M	-7.91M
Net Income	-133.35M	-102.33M	-52.37M	-42.86M	-100.61M	-7.33M
Balance Sheet
Total Assets	142.22M	238.99M	310.13M	196.59M	230.33M	44.43M
Cash, Cash Equivalents and Short-Term Investments	126.61M	171.56M	243.52M	177.60M	194.24M	43.78M
Total Debt	30.84M	29.70M	28.49M	105.00K	0.00	0.00
Total Liabilities	49.05M	57.18M	43.15M	7.81M	5.15M	63.02M
Stockholders Equity	93.17M	181.82M	266.97M	188.78M	225.18M	-18.59M
Cash Flow
Free Cash Flow	-123.75M	-86.23M	-43.09M	-35.31M	-18.00M	-7.45M
Operating Cash Flow	-123.66M	-86.22M	-43.06M	-35.15M	-17.96M	-7.45M
Investing Cash Flow	137.35M	48.03M	-171.67M	39.19M	-104.12M	0.00
Financing Cash Flow	-45.00K	6.93M	151.75M	3.91M	200.47M	44.67M

Acumen Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Neutral. The current price of 2.25 is above the 20-day moving average (MA) of 2.16, above the 50-day MA of 2.06, and above the 200-day MA of 1.59, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 51.09 is Neutral, neither overbought nor oversold. The STOCH value of 44.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABOS.

Acumen Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABOS	54 Neutral	$148.40M	-1.02	-85.93%	―	―	-60.99%
IKT	54 Neutral	$189.18M	-2.77	-131.71%	―	-100.00%	79.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$202.71M	-0.97	―	―	-63.96%	-28.50%
TCRX	49 Neutral	$54.56M	-0.81	-76.44%	―	-10.03%	11.06%
VTGN	46 Neutral	$20.78M	-0.32	―	―	-33.00%	54.91%

Acumen Pharmaceuticals Corporate Events

Acumen Updates Investor Presentation, Highlights 2026 Alzheimer’s Milestones

On January 12, 2026, Acumen Pharmaceuticals updated the corporate presentation on its investor website to incorporate new nonclinical murine brain exposure data for its Enhanced Brain Delivery (EBD™) program first shown at the 2025 Clinical Trials on Alzheimer’s Disease conference, refreshed interpretations of previously presented fluid biomarker results from its Phase 1 INTERCEPT-AD study of sabirnetug, and the formal addition of EBD-linked candidate ACU234 to its development pipeline. The materials also highlight key upcoming milestones that make 2026 a pivotal year for the company, including early 2026 data from an EBD preclinical candidate and late 2026 topline results from the fully enrolled global Phase 2 ALTITUDE-AD trial of sabirnetug, underscoring Acumen’s bid to strengthen its position in the evolving Alzheimer’s treatment landscape and signaling important inflection points ahead for investors and other stakeholders.

The most recent analyst rating on (ABOS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Acumen Pharmaceuticals stock, see the ABOS Stock Forecast page.

Acumen Pharmaceuticals Reports Q3 Financial Results

On November 12, 2025, Acumen Pharmaceuticals reported its third-quarter financial results and business updates, highlighting a cash balance of $136.1 million as of September 30, 2025, which is expected to support operations into early 2027. The company is progressing with its Phase 2 ALTITUDE-AD trial for sabirnetug in early Alzheimer’s disease, with topline results anticipated in late 2026. Additionally, Acumen announced the appointment of George Golumbeski as Chairman of the Board, enhancing its strategic leadership. The company aims to advance its Enhanced Brain Delivery program and anticipates non-clinical data in early 2026 to guide its development strategy.

The most recent analyst rating on (ABOS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Acumen Pharmaceuticals stock, see the ABOS Stock Forecast page.

Acumen Pharmaceuticals Appoints New Board Chairman

On November 10, 2025, Acumen Pharmaceuticals announced the appointment of Dr. George Golumbeski as Chairman of its Board of Directors. Dr. Golumbeski, with over 30 years of experience in the biopharmaceutical industry, is expected to bring significant expertise in strategic collaborations and partnerships, aligning with Acumen’s growth objectives and ongoing efforts to develop innovative treatments for Alzheimer’s disease.

The most recent analyst rating on (ABOS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Acumen Pharmaceuticals stock, see the ABOS Stock Forecast page.